Checks and prevention

This question needs an honest answer. A complication isn’t fate; it’s a curve whose slope isn’t clear from the start. How steep it turns doesn’t hang on one thing; but heading the list is the course blood glucose takes over the years. The evidence for this comes not from one study but two independent long follow-ups.

The big type 1 diabetes trial split participants into two arms and followed them for years past its end. Once it closed, the arms’ averages converged; on paper the gap melted. Outcomes were expected to even out too. The opposite happened: the gap on the eye, kidney and nerve side didn’t close; it widened a while longer (Lachin et al., 2021).

Type 2 diabetes showed something similar too. After tight monitoring ended, the glucose gap between groups vanished within the very first year; the small-vessel advantage, in contrast, held ten years. The gap on heart attack and death, meanwhile, grew clearer as follow-up lengthened. The literature calls this picture the legacy effect.

The curve has one more feature. Nothing is felt while it builds: eye, kidney and nerves stay quiet early on. This quiet is measured in years, not days; pain doesn’t show where the curve stands, regular measurements and exams do. The screening article covers which exams make this silent stretch visible.

So how does the body remember this? Two explanations stand out. First: in long-lived tissue (vessel-wall collagen, the eye’s and kidney’s fine structures), glucose binds permanently to proteins; the bonds stay in place for years. Second: marks forming in how the cell reads its genes, marks that aren’t erased for a long time.

The hope here shouldn’t be overstated: the effect itself isn’t endless; it fades after a window of about ten years, leaving the banked gain. The same mechanism runs in reverse too: a stretch spent high leaves its own mark. That mark is quiet as well; no pain, it shows in a record spread over years. Better read this not as blame but as a measure of what putting it off costs.

A tree planted early in the garden tells this picture well. Its shade doesn’t show that day; it appears years later. A tree planted later gives shade too; it just doesn’t bring back the summers between. The real difference in front of the house isn’t planting day but unbroken care.

So the question doesn’t close with yes or no. Not every complication is stopped in every case; delay and easing, though, are a measured result. What’s more, the years gained aren’t taken back later.

Another post covers which organs diabetes damage reaches and at which vessel scale it collects. The question here is different: why does this buildup make you feel nothing, why doesn’t screening wait for a complaint? The three places share one trait: they stay quiet early on. The body gives no alarm; you feel fine.

The eye is the clearest case. When the vessels in the retina start leaking and clogging, vision holds a long while. Only an exam of the retina catches the change; the eye post covers how.

The kidney’s silence has another cause. The organ’s capacity sits well above need; while one part strains, the rest keeps carrying the work. So albumin leaking into the urine shows up before any complaint. The nerves’ silence comes from the loss’s slow pace; you often learn of fading sensation at an exam. With protective sensation erased, a sore on the foot doesn’t hurt; noticing it falls to looking, not feeling.

An early exam has another job: it leaves a baseline later exams are measured against. With no baseline in the record, slow change doesn’t look like change; back-of-the-eye and kidney values gain meaning only when read against their own history.

So why does screening’s start shift by diabetes type? The answer hides in when the illness began. Type 1 diabetes opens with an obvious picture: its first day is roughly known, and the counter runs from that day. Screening begins a few years later, because damage needs time to build. For those diagnosed in childhood the counter runs differently: the years before puberty don’t carry the buildup at the same pace, so the first exam opens late.

Type 2 diabetes settles in quietly; the diagnosis comes years later. That gap between settling and diagnosis leaves room for damage already begun. So screening opens on diagnosis day; in some people, eye involvement turns up at the very first exam.

What waiting for a symptom costs shows up right here. After fragile new vessels form in the retina, kidney filtering power drops, or the foot’s protective sensation is erased, the list of options shortens. Early on, though, the picture is still unsettled and open to changing direction. The quiet period is measured in years, not weeks; screening’s window is that wide.

What gets noticed in the late period is known: blurred vision or floating spots, numbness and tingling in the foot, stubborn ankle swelling. Listing these isn’t diagnosing; it’s showing what screening tries to leave behind.

Frequency is set person by person; no single schedule fits everyone. What doesn’t change is the logic. It’s the same reason the car’s oil gets checked before the engine makes a noise: once it does, the cheapest repair is already past.

The first surface cigarette smoke meets on reaching the blood is the vessels’ inner lining. Smoke disrupts that lining’s working, raises clotting tendency, and lowers blood’s oxygen-carrying capacity. Diabetes already wears the same lining. The two effects overlap. The heart article describes this lining’s structure and how it wears.

The second point comes up less often. In smokers, insulin resistance measures higher than in nonsmokers; fat’s tendency to gather at the body’s middle works the same way. So smoke doesn’t stop at the vessel side; it also makes blood sugar harder to balance.

The number showing direction comes from a large review. Across eighty-nine pooled follow-up studies, smoking was seen to raise death and vascular event risk in a person with diabetes by about half. The small-vessel picture isn’t this uniform; the most consistent findings gather in kidney and nerve involvement, and especially in type 1 diabetes.

Quitting’s return must be said as it is. Weight gain is common the first year; blood sugar swings can last a few years. These swings aren’t felt. What makes them visible are measurements kept while quitting. Even so, in that review, quitters’ death risk came out markedly below continuing smokers’. It doesn’t fully reach never-smokers’ level; most of the road closes anyway.

The World Health Organization’s summary, prepared with the International Diabetes Federation, points the same way. Despite short-term weight gain, quitting pulls type 2 diabetes risk down long term, and the gain grows the longer you stay quit.

In daily life the difference shows first in small things. Your breath’s recovery time climbing the stairs, your feet warming on an evening walk, fingertip color in cold weather. A small, slow-closing crack on the foot signals that same circulation too. These aren’t measurements, but traces read in daily life.

Blame has no business here. Nicotine addiction is about the brain’s reward circuits, not willpower; quitting spreads over several tries, and trying again is an ordinary part of the process. What needs understanding is plain: in diabetes, smoking’s cost is paid not only in the lungs but across the whole vessel network.